Fig. 2: Compound dose-dependent reduction of tau in a neuronal cell model of tauopathy.

Tau-A152T (FTD19-L5-RC6) 6-week differentiated neurons were treated for 24 h, and tau protein levels and neuronal viability were measured. a–d Western blot of total tau (TAU5) and P-tau^S396, with representative blots shown on the left and mean densitometry shown on the right (b–d samples were run on the same gel, with the same vehicle sample, and image was cropped at the dotted line only for the purpose of this figure). Bands used for quantification are within brackets. Data points represent mean densitometry relative to vehicle-treated samples (a.u., arbitrary units) ± SEM of n = 4 biological replicates (n = 6 for vehicle and highest dose). e–h Tau ELISA dose-response curves. Data points represent mean tau per μg of total protein, relative to vehicle-treated samples ± SEM. Results represent n = 4 with technical replicates per ELISA plate. Statistical significance (a–h) was calculated using two-way ANOVA with post hoc Dunnett’s multiple comparisons test relative to vehicle, with ^nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. i–l Dose-response curves for neuronal viability. Data points represent mean % viability relative to vehicle ± SEM, for n = 3 biological replicates. m IF of A152T neurons with total tau (K9JA) and P-tau^S396/S404 (PHF-1) antibodies in red, and neuronal marker MAP2 in green. Scale bars are 50μm. Representative images of n = 3. Source data are provided as a Source Data file.